Clinical Trial Update: Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes [Phase 2]

View source ↗

Summary

Clinical trial evaluating empagliflozin and anakinra for postprandial hypoglycemia in patients with prediabetes has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postprandial Hypoglycemia
• Prediabetes

Drugs mentioned

• Jardiance (empagliflozin)
• KINERET (ANAKINRA)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Postprandial Hypoglycemia | Phase 2 | Status: WITHDRAWN